Abstract
Background: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The beneficial effects of HMG-CoA reductase inhibitors or statins are mainly attributed to their ability to inhibit hepatic cholesterol biosynthesis. Beyond their lipid lowering activity, ample evidence exists in support of their potent anti-inflammatory properties which initiate from the inhibition of GTPase isoprenylation, activating a cataract of secondary pathways and extend to the inhibition and blocking of immune cell activation and interaction.
Objective: To summarize the anti-inflammatory mechanisms of statins in clinical and experimental settings in cardiovascular disease.
Methods: A systematic search of PubMed and the Cochrane Database was conducted in order to identify the majority of trials, studies, current guidelines and novel articles related to the subject.
Results: In vitro, statins have immuno-modulatory and anti-inflammatory effects, and they can exert antiatherosclerotic effects independently of their hypolipidemic actions. In addition, positive results have emerged from mechanistic and experimental studies on the active role of HMG-CoA reductase inhibitors in HF. By extrapolating those data in clinical setting, we further understand how HMG-CoA reductase inhibitors can beneficially affect not only systolic but also diastolic HF.
Conclusion: In this review article, we present the basic pathophysiologic data supporting the anti-inflammatory actions of statins in clinical and experimental settings and we link these mechanisms with confirmatory clinical data on the potent non lipid lowering effects of HMG-CoA reductase inhibitors.
Keywords: Statins, inflammation, atherosclerosis, heart failure, coronary artery disease, hypertension.
Current Pharmaceutical Design
Title:Statins and Inflammation in Cardiovascular Disease
Volume: 23 Issue: 46
Author(s): Georgia Vogiatzi, Evangelos Oikonomou*, Gerasimos Siasos, Sotiris Tsalamandris, Alexandros Briasoulis, Emmanuel Androulakis, George Latsios, Spyridon Papaioannou, Konstantinos Tsioufis and Dimitris Tousoulis
Affiliation:
- 1st Department of Cardiology, ‘Hippokration' Hospital, University of Athens Medical School, Athens,Greece
Keywords: Statins, inflammation, atherosclerosis, heart failure, coronary artery disease, hypertension.
Abstract: Background: Chronic inflammation and immune system activation underlie a variety of seemingly unrelated cardiac conditions including not only atherosclerosis and the subsequent coronary artery disease but also peripheral artery disease, hypertension with target organ damage and heart failure. The beneficial effects of HMG-CoA reductase inhibitors or statins are mainly attributed to their ability to inhibit hepatic cholesterol biosynthesis. Beyond their lipid lowering activity, ample evidence exists in support of their potent anti-inflammatory properties which initiate from the inhibition of GTPase isoprenylation, activating a cataract of secondary pathways and extend to the inhibition and blocking of immune cell activation and interaction.
Objective: To summarize the anti-inflammatory mechanisms of statins in clinical and experimental settings in cardiovascular disease.
Methods: A systematic search of PubMed and the Cochrane Database was conducted in order to identify the majority of trials, studies, current guidelines and novel articles related to the subject.
Results: In vitro, statins have immuno-modulatory and anti-inflammatory effects, and they can exert antiatherosclerotic effects independently of their hypolipidemic actions. In addition, positive results have emerged from mechanistic and experimental studies on the active role of HMG-CoA reductase inhibitors in HF. By extrapolating those data in clinical setting, we further understand how HMG-CoA reductase inhibitors can beneficially affect not only systolic but also diastolic HF.
Conclusion: In this review article, we present the basic pathophysiologic data supporting the anti-inflammatory actions of statins in clinical and experimental settings and we link these mechanisms with confirmatory clinical data on the potent non lipid lowering effects of HMG-CoA reductase inhibitors.
Export Options
About this article
Cite this article as:
Vogiatzi Georgia , Oikonomou Evangelos *, Siasos Gerasimos, Tsalamandris Sotiris , Briasoulis Alexandros, Androulakis Emmanuel, Latsios George, Papaioannou Spyridon , Tsioufis Konstantinos and Tousoulis Dimitris , Statins and Inflammation in Cardiovascular Disease, Current Pharmaceutical Design 2017; 23 (46) . https://dx.doi.org/10.2174/1381612823666171009141201
DOI https://dx.doi.org/10.2174/1381612823666171009141201 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets Zolpidem Arousing Effect in Persistent Vegetative State Patients: Autonomic, EEG and Behavioral Assessment
Current Pharmaceutical Design Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non–Small Cell Lung Cancer Models
Current Cancer Drug Targets The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review
Current Drug Safety Neuronal and Vascular Oxidative Stress in Alzheimers Disease
Current Neuropharmacology Hypertension and Aortic Stenosis: A Review
Current Hypertension Reviews OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy
Cardiovascular & Hematological Disorders-Drug Targets IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews Current Approach to the Diagnosis and Treatment of Femoral-Popliteal Arterial Disease. A Systematic Review
Current Cardiology Reviews Editorial [Hot Topic: Matrix Metalloproteinases in Cardiovascular Disease (Guest Editors: N. Papageorgiou & D. Tousoulis)]
Current Topics in Medicinal Chemistry Subject Index to Volume 2
Current Vascular Pharmacology Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
Current Medicinal Chemistry Licochalcone B Arrests Cell Cycle Progression and Induces Apoptosis in Human Breast Cancer MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
Current Drug Targets Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare
Reviews on Recent Clinical Trials LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry